15 results about "Amyloid beta proteins" patented technology

The present invention relates to a composition for preventing, alleviating or treating cognitive disorders or Alzheimer's disease, comprising a Lactobacillus delbrueckii subsp. Lactis strain as an active ingredient. The present invention provides a composition for preventing, alleviating or treating cognitive disorders or Alzheimer's disease (AD), comprising a Lactobacillus delbrueckii subsp. Lactis strain as an active ingredient. The strain of the present invention has excellent effects of reducing amyloid beta protein (A beta) or tau protein (Tau) and improving cognitive function, and thus can be usefully used as a composition for preventing, alleviating or treating cognitive impairment or AD.

The present disclosure relates generally to compositions and methods for determining whether a patient suffers from a traumatic brain injury (TBI) by detecting the presence of an amyloid beta protein in an eye of the patient. Also provided are compositions and methods for preparing a patient for diagnosis and treatment of traumatic brain injury (TB).

To provide technology that can be used to inhibit aggregation of β-amyloid protein (Aβ) and microtubule-binding protein Tau, which bring about senile plaque (senile plaque: AP) and neurofibrillary tangle (Neurofibrillary Tangle: NFT).SOLUTION: The present invention provides a protein aggregation inhibitor containing mesostructured particles of calcium hydrogen carbonate as an active ingredient.SELECTED DRAWING: Figure 2

The present disclosure relates generally to compositions and methods for determining whether a patient has traumatic brain injury (TBI) by detecting the presence of amyloid beta protein in the eye of the patient. Compositions and methods for preparing a patient to diagnose and treat traumatic brain injury (TBI) are also provided.

Provided herein are compounds, methods and compositions for determining whether a patient has a neurological disease or disorder is provided, comprising detecting the presence of a target protein, or an accumulated mass thereof, for example, amyloid beta protein or phosphorylated tau protein, or an accumulated mass thereof, in a tissue or a sample of the patient. The detecting may comprise contacting the target protein with a compound described herein.

The present disclosure is directed to improved peptide immunogen constructs targeting portions of the Tau protein for the treatment and / or prevention of tauopathies. The present disclosure is also directed to improved peptide immunogen constructs targeting portions of the amyloid beta protein for the treatment and / or prevention of tauopathies. The present disclosure is also directed to compositions and kits containing the peptide immunogen constructs, in particular compositions and kits comprising combinations of various peptide immunogen constructs. Methods of making and using the peptide immunogen constructs, and antibodies produced by the peptide immunogen constructs, are also provided herein. In some aspects, the disclosure is directed to compositions comprising peptide immunogen constructs based on portions of the Tau protein and peptide immunogen constructs based on portions of the amyloid beta protein, and use of these peptide immunogen constructs and compositions in therapeutic methods.

Provided herein are compounds, methods, and compositions for determining whether a patient has a neurological disease or condition, comprising detecting the presence or cumulative mass thereof of a detectable target protein in a tissue or sample of the patient, such as the presence or cumulative mass thereof of amyloid beta protein or phosphorylated tau protein. The detection may comprise contacting the target protein with a compound described herein.

The present disclosure relates to improved peptide immunogen constructs targeting a portion of the Tau protein for use in the treatment and / or prevention of Tau protein pathologies. The present disclosure also relates to improved peptide immunogen constructs targeting a portion of amyloid beta for use in the treatment and / or prevention of tauopathies. The present disclosure also relates to compositions and kits comprising the peptide immunogen constructs, in particular compositions and kits comprising a combination of various peptide immunogen constructs. Also provided herein are methods of making and using the peptide immunogen constructs, as well as antibodies produced by the peptide immunogen constructs. In some aspects, the disclosure relates to compositions comprising a peptide immunogen construct based on a portion of the Tau protein and a peptide immunogen construct based on a portion of the amyloid beta protein, and the use of these peptide immunogen constructs and compositions in methods of treatment.

The present invention provides a prophylactic or therapeutic agent for dementia, an agent for enhancing memory and / or cognitive function, an agent for inhibiting the synapse loss action of amyloid beta protein, an amyloid beta protein production inhibitor, and an amyloid beta protein clearance promoter, each of which contains, as an active ingredient, a Crtac1B protein or a C-terminal region fragment thereof, a vector capable of expressing a Crtac1B protein or a C-terminal region fragment thereof, or a cell expressing a Crtac1B protein or a C-terminal region fragment thereof.

The present invention relates to use of a peptide as a therapeutic agent for degenerative brain diseases. Specifically, it was identified that the peptide of the present invention targeted microglia to induce the state of inflammatory microglia to be an anti-inflammatory state in a disease environment, thereby reducing neuroinflammation and increasing a phagocytosis function, leading to an effect of removing amyloid beta protein, and the peptide of the present invention exhibited effects of reducing amyloid-beta, recovering synaptic plasticity, and alleviating cognitive disorders related to anxiety, learning, and memory in a degenerative brain disease animal model. Therefore, the peptide of the present invention can be helpfully used as an active ingredient of a composition for preventing or treating degenerative brain diseases, and the resulting cognitive disorders, learning disorders, or memory disorders.

The present invention relates to a composition for preventing, alleviating or treating cognitive impairment or Alzheimer's disease, comprising a Lactobacillus delbrueckii subsp. lactis strain as an active ingredient. The present invention provides a composition for preventing, alleviating or treating cognitive impairment or Alzheimer's disease (AD), comprising a Lactobacillus delbrueckii subsp. lactis strain as an active ingredient. The strain of the present invention has the excellent effects of reducing amyloid beta protein (Aβ) or tau protein (Tau) and improving cognitive function, and thus can be effectively used as a composition for preventing, alleviating or treating cognitive impairment or AD.

The present invention provides: a prophylactic or therapeutic agent for dementia; an agent for enhancing memory and / or cognitive function; an agent for inhibiting the synaptic loss action of amyloid beta protein; an agent for inhibiting amyloid beta protein production; and an agent for promoting amyloid beta protein clearance, each of which contains, as an active ingredient, a Crtac1B protein or a C-terminal region fragment thereof, a vector capable of expressing the Crtac1B protein or the C-terminal region fragment thereof, or a cell expressing the Crtac1B protein or the C-terminal region fragment thereof.

Murine, chimeric or humanized anti-Abeta antibody having a specific CDR region, an antigen-binding fragment thereof, a pharmaceutical composition thereof, and usage thereof. Use of a humanized anti-Abeta antibody for the preparation of drugs for the treatment of a disease or disorder (such as Alzheimer's disease) caused by amyloid beta protein.

Provided herein are compounds, methods and compositions for determining whether a patient has a neurological disease or disorder is provided, comprising detecting the presence of a detectable target protein, or an accumulated mass thereof, for example, amyloid beta protein or phosphorylated tau protein, or an accumulated mass thereof, in a tissue or a sample of the patient. The detecting may comprise contacting the target protein with a compound described herein.

Murine, chimeric or humanized anti-Abeta antibody having a specific CDR region, an antigen-binding fragment thereof, a pharmaceutical composition thereof, and usage thereof. Use of a humanized anti-Abeta antibody for the preparation of drugs for the treatment of a disease or disorder (such as Alzheimer's disease) caused by amyloid beta protein.